Tags

Type your tag names separated by a space and hit enter

Vaginal microbicides and their delivery platforms.
Expert Opin Drug Deliv. 2014 May; 11(5):723-40.EO

Abstract

INTRODUCTION

HIV type 1 infection, despite having fallen by one-third over the past decade, remains a global health concern affecting millions of individuals worldwide. A focal point in contemporary research aimed at global HIV prevention has been the development of safe and efficacious coitally dependent and coitally independent anti-HIV microbicides to curb heterosexual HIV transmission. Despite extensive research efforts to develop novel vaginal antiretroviral (ARV) formulations and intravaginal ring delivery systems, the clinical advancement of microbicides with improved safety, efficacy and tolerability has significantly lagged behind.

AREAS COVERED

This review focuses on the current status of both coitally dependent and coitally independent delivery platforms designed to increase user acceptability and clinical effectiveness of anti-HIV microbicides. The clinical failure of several vaginal microbicide candidates has propelled the field to mechanism-based ARV candidates that act more specifically on viral receptors, viral enzymes and host proteins. Consequently, improved vaginal microbicide delivery strategies that achieve uniform drug distribution with enhanced solubility, sustained drug release, improved product adherence with reduced dosing frequency and lack of effect on the vaginal mucosa and microbiota are being sought.

EXPERT OPINION

Clinical success with vaginal microbicides may best be achieved through the combined effects of ARV compounds that exhibit different mechanisms of action with potent activity against multidrug-resistant HIV and efficacious delivery systems.

Authors+Show Affiliations

Children's Center for Cancer and Blood Diseases , Children's Hospital Los Angeles, Smith Research Tower Suite 316, 4650 Sunset Boulevard, CHLA Mailstop 160, Los Angeles, CA , USA fmuckun@chla.usc.edu.No affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

24506783

Citation

D'Cruz, Osmond J., and Fatih M. Uckun. "Vaginal Microbicides and Their Delivery Platforms." Expert Opinion On Drug Delivery, vol. 11, no. 5, 2014, pp. 723-40.
D'Cruz OJ, Uckun FM. Vaginal microbicides and their delivery platforms. Expert Opin Drug Deliv. 2014;11(5):723-40.
D'Cruz, O. J., & Uckun, F. M. (2014). Vaginal microbicides and their delivery platforms. Expert Opinion On Drug Delivery, 11(5), 723-40. https://doi.org/10.1517/17425247.2014.888055
D'Cruz OJ, Uckun FM. Vaginal Microbicides and Their Delivery Platforms. Expert Opin Drug Deliv. 2014;11(5):723-40. PubMed PMID: 24506783.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Vaginal microbicides and their delivery platforms. AU - D'Cruz,Osmond J, AU - Uckun,Fatih M, Y1 - 2014/02/08/ PY - 2014/2/11/entrez PY - 2014/2/11/pubmed PY - 2014/6/13/medline SP - 723 EP - 40 JF - Expert opinion on drug delivery JO - Expert Opin Drug Deliv VL - 11 IS - 5 N2 - INTRODUCTION: HIV type 1 infection, despite having fallen by one-third over the past decade, remains a global health concern affecting millions of individuals worldwide. A focal point in contemporary research aimed at global HIV prevention has been the development of safe and efficacious coitally dependent and coitally independent anti-HIV microbicides to curb heterosexual HIV transmission. Despite extensive research efforts to develop novel vaginal antiretroviral (ARV) formulations and intravaginal ring delivery systems, the clinical advancement of microbicides with improved safety, efficacy and tolerability has significantly lagged behind. AREAS COVERED: This review focuses on the current status of both coitally dependent and coitally independent delivery platforms designed to increase user acceptability and clinical effectiveness of anti-HIV microbicides. The clinical failure of several vaginal microbicide candidates has propelled the field to mechanism-based ARV candidates that act more specifically on viral receptors, viral enzymes and host proteins. Consequently, improved vaginal microbicide delivery strategies that achieve uniform drug distribution with enhanced solubility, sustained drug release, improved product adherence with reduced dosing frequency and lack of effect on the vaginal mucosa and microbiota are being sought. EXPERT OPINION: Clinical success with vaginal microbicides may best be achieved through the combined effects of ARV compounds that exhibit different mechanisms of action with potent activity against multidrug-resistant HIV and efficacious delivery systems. SN - 1744-7593 UR - https://www.unboundmedicine.com/medline/citation/24506783/Vaginal_microbicides_and_their_delivery_platforms_ L2 - https://www.tandfonline.com/doi/full/10.1517/17425247.2014.888055 DB - PRIME DP - Unbound Medicine ER -